Enzalutamide Production Cost Reports

The report provides a detailed analysis essential for establishing an Enzalutamide production plant. It encompasses all critical aspects necessary for Enzalutamide production, including the cost of Enzalutamide production, Enzalutamide plant cost, Enzalutamide production costs, and the overall Enzalutamide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Enzalutamide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Enzalutamide is an antiandrogen medication used in the treatment of different stages of prostate cancer. It is mostly given to patients with metastatic hormone-sensitive prostate cancer (the cancer that spreads to other parts of the body) and hormone-insensitive or castration-resistant prostate cancer. It can also be used in non-metastatic castration-sensitive prostate cancer patients with a high risk of recurrence post-treatment. It works by blocking testosterone and this might contribute to slowing down the way cancer cells grow. Furthermore, patients with specific gene mutations that are associated with cancer can also use it together with talazoparib.

The market for Enzalutamide is driven by its application as an antiandrogen medication used for the treatment of different stages of prostate cancer, which significantly promotes its demand in the pharmaceutical and medical industries. The widespread occurrence of prostate cancer is significantly increasing the demand for Enzalutamide. Additionally, the efficacy of the drug in different stages of prostate cancer amplifies its market appeal. Moreover, the drug’s ability to improve the overall survival rates and quality of life for patients further boosts its demand.

Furthermore, the utilization of Enzalutamide in combination with other treatments, such as talazoparib for patients with specific genetic mutations, expands its application and increases its market potential. Overall, industrial Enzalutamide procurement is influenced by its application in the pharmaceutical and medical industries, rising cases of prostate cancer, efficacy in different stages of cancer, improved overall survival rates, combination therapy, increasing healthcare awareness, and regulatory approvals.

Raw Material for Enzalutamide Production

According to the Enzalutamide production plant project report, the key raw material used in the production of Enzalutamide includes 4-bromo-2-fluoro-benzonicacid.

Production Process of Enzalutamide

The extensive Enzalutamide production cost report consists of the following major industrial production process:

• Production from 4-bromo-2-fluoro-benzonicacid: The production process of Enzalutamide starts with the methyl esterification reaction of the starting compound catalyzed by sulfuric acid in methanol under reflux to form methyl 4-bromo-2-fluoro benzoate. The compound undergoes Ullmann reaction and ligation with 2-amino-2-methylpropionic acid to give an intermediate. The intermediate is reacted with thionyl chloride in refluxing methanol to form 2-fluoro-4-[(2-methoxy-1,1-dimethyl-2-oxoethyl)amino]-methyl ester. The compound is reacted with 4-cyano-3-(trifluoromethyl)phenyl isothiocyanate in the presence of DMSO to form the final intermediate. Finally, the intermediate undergoes a methyl amidation reaction to produce Enzalutamide.

Enzalutamide, commercially known as Xtandi, is an off-white solid having the molecular formula C21H16F4N4O2S and a molecular weight of 464.4 g/mol. It is almost insoluble in water, with an estimated water solubility of around 0.00136 mg/mL. It is soluble to some extent in isopropanol and highly soluble in acetonitrile. It has a melting point of 201 °C. It has a log P value of 3. The value of its dissociation constant, pKa, is 13.05. It is a non-steroidal antiandrogen medication used to treat different stages of prostate cancer.